Cancer chronotherapy: Principles, applications, and perspectives

Cancer

Volumn 97, Issue 1, 2003, Pages 155-169

  Mormont, Marie Christine ^a   Levi, Francis ^a  

^a Lab 'Rythmes Biologiques C   (France)

Author keywords

Chronopharmacology; Chronotherapy; Circadian rhythms; Colorectal carcinoma; Quality of life; Survival

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PIRARUBICIN; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL MODEL; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONOBIOLOGY; CHRONOTHERAPY; COLORECTAL NEOPLASMS; DRUG TOLERANCE; HUMANS; MODELS, BIOLOGICAL; PROGNOSIS; QUALITY OF LIFE;

EID: 0037217052     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11040     Document Type: Article

References (95)

1. Plautz JD, Kaneko M, Hall JC, et al. Independent photoreceptive circadian clocks throughout Drosophila. Science. 1997;278:1632-1635.
2. Vitaterna MH, King DP, Chang AM, et al. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science. 1994;264:719-725.
3. Reinberg A, Touitou Y, Restoin A, Migraine C, Lévi F, Montagner H. The genetic background of circadian and ultradian rhythm patterns of 17-hydroxycorticosteroids: A cross-twin study. J Endocrinol. 1985;105:247-253.
4. Linkowski P, Van Onderbergen A, Kerkhofs M, Bosson D, Mendlewicz J, Van Cauter E. Twin study of the 24-h cortisol profile: Evidence for genetic control of the human circadian clock. Am J Physiol. 1993;264:E173-E181.
5. Mendlewicz J, Linkowski P, Kerkhofs M, Leproult R, Copinschi G, Van Cauter E. Genetic control of 24-hour growth hormone secretion in man: A twin study. J Clin Endocrinol Metab. 1999;84:856-862.
6. Tei H, Okamura H, Shigeyoshi Y, et al. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature. 1997;389:512-516.
7. Moore RY, Eichler VB. Central neural mechanism in diurnal rhythm regulation and neuroendocrine responses to light. Psychoneuroendocrinology. 1972;1:265-279.
8. Stephan FK, Zucker I. Circadian rhythms in drinking behaviour and locomotor activity of rats are eliminated by hypothalamic lesions. Proc Natl Acad Sci U S A. 1972;69:1583-1586.
9. Ralph MR, Foster RG, Davis FC, Menaker M. Transplanted suprachiasmatic nucleus determines circadian period. Science. 1990;247:975-978.
10. Rosenwasser AM, Wirz-Justice A. Circadian rhythms and depression: Clinical and experimental models. In: Redfern P, Lemmer B, editors. Physiology and Pharmacology of Biological Rhythms. Berlin: Springer-Verlag, 1997:457-485.
11. Mormont MC, Lévi F. Circadian-system alterations during cancer processes: A review, Int J Cancer. 1997;70:241-247.
12. Burns RE, Scheving LE, Tsai TH. Circadian rhythms in DNA synthesis and mitosis in normal mice and in mice bearing the lewis lung carcinoma. Eur J Cancer. 1979;15:233-242.
13. Barbason H, Betz EH. Liver cell control after discontinuation of DENA feeding in hepatocarcinogenesis. Eur J Cancer. 1981;17:149-156.
14. Bouzahzah B. Influence de Différents Promoteurs sur la Prolifération Cellulaire du Foie de Rat Normal et Précancéreux: Rôle des Corticoïdes et des Rythmes Circadiens [Ph.D. thesis]. Liàge, Belgium: Université de Liège, 1990.
15. Kampfschmidt RF, Upchurch HF. Daily variation of body temperature, liver catalase activity, and plasma iron concentration in normal and tumor-bearing rats. Proc Soc Exp Biol Med. 1970;134:527-529.
16. Sothern RB, Hrushesky WJM, Halberg F, Haus E, Kennedy BJ. Circadian temperature rhythm in LOU rats with and without immunocytoma during polychronochemotherapy with adriamycin and cis-diamminedichloroplatinum. Chronobiologia. 1978;5:216.
17. Hori K, Zhang QH, Salto S. Variation of growth rate of rat tumor during a light-dark cycle: Correlation with circadian fluctuation in tumor blood flow. Br J Cancer. 1995;71:1163-1168.
18. Voutilainen A. Uber die 24-stunden-rhythmik der mitozfrequenz in malignen tumoren. Acta Pathol Microbiol Scand. 1953;99(Suppl):1-104.
19. Tahti E. Studies of the effect of X-irradiation on 24 hour variations in the mitotic activity in human malignant tumors. Acta Pathol Microbiol Scand. 1956;117:1-61.
20. Garcia-Sainz M, Halberg F. Mitotic rhythms in human cancer reevaluated by electronic computer programs. Evidence for chronopathology. J Natl Cancer Inst. 1966;37:279-292.
21. Zagula-Mally ZW, Cardoso SS, Williams D, et al. Time point differences in skin mitotic activity of actinic keratoses and skin cancers. In: Reinberg A, Halberg F, editors. Chronopharmacology. New York: Pergamon Press, 1979:399-402.
22. Klevecz R, Shymko R, Braly P. Circadian gating of S phase in human ovarian cancer. Cancer Res. 1987;47:6267-6271.
23. Klevecz R, Braly P. Circadian and ultradian cytokinetic rhythms of spontaneous human cancer. Ann NY Acad Sci. 1991;618:257-276.
24. Smaaland R, Lote K, Sothern RB, et al. DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate variation depending on circadian stage of cell sampling. Cancer Res. 1993;53:3129-3138.
25. Gautherie M, Gros C. Circadian rhythm alteration of skin temperature in breast cancer. Chronobiologia. 1974;4:1-17.
26. Mansfield CM, Carabasi RA, Wells W, et al. Circadian rhythm in the skin temperature of normal and cancerous breasts. Int J Chronobiol. 1973;1:235-243.
27. Smaaland R, Laerum OD, Lote K, et al. DNA synthesis in human bone marrow is circadian stage dependent. Blood. 1991;77:2603-2611.
28. Smaaland R, Abrahamsen JF, Svardal AM, et al. DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer, 1992;66:39-45.
29. Tamarkin L, Danforth D, Lichter A, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science. 1982;216:1003-1005.
30. Bartsch C, Bartsch H, Flüchter SH, Mecke D, Lippert TH. Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Ann N Y Acad Sci. 1994;719:502-525.
31. Mormont MC, Hecquet B, Bogdan A, et al. Selection and validation of a non-invasive test of cortisol circadian rhythm in cancer patients and control subjects. Int J Cancer. 1998;78:421-424.
32. Touitou Y, Lévi F, Bogdan A, et al. Circadian desynchronization of blood variables in patients with metastatic breast cancer. Role of prognostic factors. J Cancer Res Clin Oncol. 1995;121:181-188.
33. Touitou Y, Bogdan A, Lévi F, et al. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients. Relationships with tumor marker antigens. Br J. Cancer. 1996;74:1248-1252.
34. Benavides M. Cancer Avancé de l'Ovaire: Approche Chronobiologique Comme Nouvelle Stratégie du Traitement et de la Surveillance Clinique et Biologique [Ph.D. thesis]. Paris: Université Paris XI, 1991.
35. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994-1000.
36. Dowse HB, Ringo JM. The search for hidden periodicities in biological rime series revisited. J Theor Biol. 1989;139:487-515.
37. Minors DS, Akerstedt T, Atkinson G, et al. The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients. Chronobiol Int. 1996;13:27-34.
38. Mormont MC, Bleuzen P, Waterhouse J, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038-3045.
39. Mormont MC, Waterhouse J. Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiol Int. 2002;19:313-323.
40. Mormont MC, Boughattas N, Lévi F. Mechanisms of circadian rhythms in the toxicity and the efficacy of anticancer drugs: Relevance for the development of new analogs. In: Lemmer B, editor. Chronopharmacology: Cellular and Biochemical Interactions. New York: Marcel Dekker, 1989:395-437.
41. Lévi F. Chronopharmacology of anticancer agents. In: Redfern P, Lemmer B, editors. Physiology and Pharmacology of Biological Rhythms. Berlin: Springer-Verlag, 1997:299-331.
42. Lévi F, Hrushesky W, Blomquist CH, et al. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982;42:950-955.
43. Boughattas NA, Lévi F, Hecquet B, et al. Circadian rime dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol. 1988;96:233-247.
44. Boughattas N, Lévi F, Fournier C, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res. 1989;49:3362-3368.
45. Lévi F, Mechkouri M, Roulon A, et al. Circadian rhythm in tolerance of mice for the new anthracycline analog 4'-tetrahydropyranyladriamycin (THP). Eur J Cancer Clin Oncol. 1985;121:1245-1251.
46. Lévi F, Tampellini M, Metzger G, et al. Circadian changes in mitoxantrone toxicity in mice: Relationship with plasma pharmacokinetics. Int J Cancer. 1994;59:543-547.
47. Mormont MC, Beretska JS, Mushiya T, et al. Circadian dependency of vinblastine toxicity. Ann Rev Chronopharmacol. 1986;3:187-190.
48. Filipski E, Amat S, Lemaigre G, et al. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice. J Pharmacol Exp Ther. 1999;289:231-235.
49. Granda TG, Lévi F. Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiol Int. 2002;19:21-41.
50. Tampellini M, Filipski E, Liu X-H, et al. Circadian rhythm in docetaxel tolerability and efficacy in mice. Cancer Res. 1998;58:3896-3904.
51. Granda TG, D'Attino RM, Filipski E, et al. Circadian optimization of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer. 2002;86:999-1005.
52. Zhang R, Lu Z, Liu T, et al. Relationship between circadiandependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: Possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 1993;53:2816-2822.
53. Li XM, Metzger G, Filipski E, et al. Pharmacologic modulation of reduced glutathione (GSH) circadian rhythms by buthionine sulfoximine (BSO): Relationship with cisplatin (CDDP) toxicity in mice. Toxicol Appl Pharmacol. 1997;143:281-290.
54. Ohdo S, Makinosumi T, Ishizaki T, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther. 1997;283:1383-1388.
55. Petit E, Milano G, Lévi F, et al. Circadian varying plasma concentration of 5-FU during 5-day continuous venous infusion at constant rate in cancer patients. Cancer Res. 1988; 48:1676-1679.
56. Thiberville L, Compagnon C, Moore N, et al. Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol. 1994;35:64-70.
57. Metzger G, Massari C, Etienne MC, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in cancer patients. Clin Pharmacol Ther. 1994;56:190-201.
58. Fleming GF, Schilsky RL, Mick R, et al. Circadian variation of 5-fluorouracil (5-FU) and cortisol plasma levels during continuous-infusion 5-FU and leucovorin (LV) in patients with hepatic or renal dysfunction. Proc Am Soc Clin Oncol. 1994; 13:139.
59. Bressole F, Joulia JM, Pinguet F, et al. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 1999;44:295-302.
60. Takimoto CH, Yee LK, Venzon DJ. et al. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res. 1999;5:1347-1352.
61. Lévi F, Metzger G, Bailleul F, et al. Circadian-varying plasma pharmacokinetics of doxorubicin (DOX) despite continuous infusion at constant rate [abstract]. Proc Am Assoc Cancer Res. 1986;27:693.
62. Focan C, Doalto L, Mazy V, et al. Vindesine en perfusion continue de 48 heures (suivie de cisplatine) dans le cancer pulmonaire avancé. Données chronopharmacocinétiques et efficacité clinique. Bull Cancer. 1989;76:909-912.
63. Squalli A, Oustrin J, Houin G, et al. Clinical chronopharmacokinetics of doxorubicin (DXR). Ann Rev Chronopharmacol. 1989;5:393-396.
64. Harris B, Song R, Soong S, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: Evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluoroura cil by protracted continuous infusion. Cancer Res. 1990;50: 197-201.
65. Buchi KN, Moore JG, Hrushesky WJM, et al. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 1991;101:410-415.
66. Focan C. Sequential chemotherapy and circadian rhythm in human solid tumors. Cancer Chemother Pharmacol. 1979;3: 197-202.
67. Deka AC. Application of Chronobiology to Radiotherapy to Tumours of the Oral Cavity [M.D. thesis]. Chandigarh, India: Post-Graduate Institute of Medical Education and Research, 1975.
68. Rivard G, Infante-Rivard C, Hoyoux C, et al. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: Better in the evening. Lancet 1985;ii:1264-1266.
69. Hrushesky W. Circadian timing of cancer chemotherapy. Science. 1985;228:73-75.
70. Lévi F, Benavides M, Chevelle C, et al. Chemotherapy of advanced ovarian cancer with 4'-0-tetrahydropyranyl adriamycin (THP) and cisplatin: A phase II trial with an evaluation of circadian timing and dose intensity. J Clin Oncol. 1990;8:705-714.
71. Hrushesky W, von Roemeling R, Lanning RM, et al. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol. 1990;8:1504-1513.
72. Deprés-Brummer P, Lévi F, Di Palma M, et al. A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. J Immunother. 1991;10:440-447.
73. Deprés-Brummer P, Bertheault-Cvitkovic F, Lévi F, et al. Circadian rhythm modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil and folinic acid: Preliminary results of a Phase I trial. J Infus Chemother. 1995;5:144-147
74. Focan C, Denis B, Kreutz F, Focan-Henrard D, Lévi F. Ambulatory chronotherapy with 5-fluorouracil, folinic acid and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. J Infus Chemother. 1995;5:148-152.
75. Lévi F, Soussan A, Adam R, et al. A Phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. J Infus Chemother. 1995;5:153-158.
76. Garufi C, Lévi F, Aschelter AM, et al. A Phase I trial of five day chronomodulated infusion of 5-fluorouracil and I-folinic acid in patients with metastatic colorectal cancer. Eur J Cancer. 1997;33:1566-1571.
77. Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 1990;82:1046-1050.
78. Lévi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 1993;29:1280-1284.
79. Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69:893-900.
80. Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Natl Cancer Inst. 1994;86:1608-1617.
81. Lévi F, Zidani R, Misset JL, for the International Organization for Cancer Chronotherapy. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997;350: 681-686.
82. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol. 1996;14: 2950-2958.
83. Lévi F, Zidani R, Brienza S, et al. A multicenter evaluation of intensified, ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer. 1999;85:2532-2540.
84. Giacchetti S, Itzhaki M, Gruia G, et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999,10:663-669.
85. Born J, Lange T, Hansen K, Mölle M, Fehm HL. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol. 1997;158:4454-4464.
86. Deprés-Brummer P, Lévi F, Metzger G, Touitou Y. Light-induced suppression of the rat circadian system. Am J Physiol. 1995;268:r1111-r1116.
87. Filipski E, King VM, Li XM, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002; 94:690-697.
88. Curé H, Chevalier V, Adenis A, et al. Phase II trial of chronomodulated infusion of high-dose 5-fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. Anticancer Res. 2000;20:4649 -4654.
89. Curé H, Chevalier V, Adenis A, et al. Phase II trial of chronomodulated infusion of high-dose 5-fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol. 2002;20:1175-1181.
90. Bjarnason GA, Marsh R, Chu NM, Kerr I, Franssen E. Phase II study of 5-fluorouracil (FU) and leucovorin (LV) by a 14 day chronomodulated infusion in patients with metastatic colorectal cancer (abstr. #1058). 34th Annual Meeting Am. Soc. Clin. Oncol., Orlando, USA, May 16-19, 1998. Proc Am Soc Clin Oncol 1998;17:275a.
91. Brienza S, Lévi F, Valori VM, et al. Intensified (every 2 weeks) chronotherapy with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) in previously treated patients with metastatic colorectal cancer. (abstr. #577). 29th Annual Meeting Am. Soc. Clin. Oncol., Orlando, USA, May 16-18, 1993. Proc Am Soc Clin Oncol. 1993;12:197.
92. Giacchetti S, Perpoint B, Zidani R, et al. for the International Organization of Cancer. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147.
93. Giacchetti S, Perpoint B, Zidani R, et al., for the International Organization of Cancer. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. Update. Classic papers and current comments, highlights of gastrointestinal cancer research. A best of JCO. J Clin Oncol. 2002;6:885-897.
94. Lévi F. From circadian rhythms to cancer chemotherapeutics. Chronobiol Int. 2002;19:1-19.
95. Condert B, Focan C, Donato di Paola E, Lévi F for the EORTC chronotherapy Group (CTG). It's time for chronotherapy! Eur J Cancer. 2002;38(Suppl 4):50-53.